Growth Stalk Holdings Past Earnings Performance
Past criteria checks 0/6
Growth Stalk Holdings's earnings have been declining at an average annual rate of -28.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 144.2% per year.
Key information
-28.6%
Earnings growth rate
23.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 144.2% |
| Return on equity | -81.1% |
| Net Margin | -53.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Growth Stalk Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | 0 | 1 | 0 |
| 31 Mar 23 | 0 | 0 | 1 | 0 |
| 31 Dec 22 | 0 | 0 | 1 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
Quality Earnings: GSTK is currently unprofitable.
Growing Profit Margin: GSTK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GSTK's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GSTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GSTK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: GSTK has a negative Return on Equity (-81.1%), as it is currently unprofitable.